Securities code: Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) securities abbreviation: Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) No.: 2022047
Shenzhen Salubris Pharmaceuticals Co.Ltd(002294)
Announcement on the progress of cash management using some idle raised funds
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without falsehood
False records, misleading statements or material omissions.
Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) (hereinafter referred to as “the company” or ” Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) “) held the 16th meeting of the 5th board of directors and the 13th meeting of the 5th board of supervisors on June 30, 2021, deliberated and adopted the proposal on cash management of using part of idle raised funds. In order to improve the use efficiency of idle raised funds, without affecting the construction of raised funds and the normal operation of the company, It is agreed that the company and its wholly-owned subsidiary (the company of the raised capital investment project) use the idle raised capital of no more than RMB 800 million for cash management. The above amount can be jointly used by the company and its wholly-owned subsidiary (the company of the raised capital investment project), and the operation management is authorized to be responsible for the specific implementation of relevant matters. The authorization period is valid within one year from the date of deliberation and approval of the board of directors. The independent director of the company and the sponsor Huaying Securities Co., Ltd. expressed their consent. For details, please refer to China Securities Journal, securities times and www.cninfo.com on July 2, 2021 info. com. cn. Announcement on cash management of using some idle raised funds.
1、 Cash management this time
Recently, the company applied to Agricultural Bank Of China Limited(601288) Shenzhen Pingshan sub branch for “zenglifeng” portfolio deposit, as follows:
1. Client: Shenzhen Salubris Pharmaceuticals Co.Ltd(002294)
2. Trustee: Agricultural Bank Of China Limited(601288) Shenzhen Pingshan sub branch
3. Product type: combined deposit
4. Purchase amount: RMB 800 million
5. Product term: there is no fixed term and can be withdrawn at any time
6. Product value date: May 20, 2022
7. Source of funds: idle raised funds
8. Expected annualized rate of return: 3.5%
9. Product income Description: zenglifeng portfolio deposit is a RMB liability product opened by Agricultural Bank Of China Limited(601288) Shenzhen Branch of China. After signing the agreement, the company will calculate interest according to the interest rate corresponding to the product on the premise that the minimum retained amount and cumulative accumulation meet the conditions agreed in the agreement, so that the company can enjoy current convenience and different interest rate income.
10. Description of association relationship: the company has no association relationship with Agricultural Bank Of China Limited(601288) Shenzhen Pingshan sub branch.
2、 Risk and risk control measures
(I) risk warning
The product selected for this cash management is portfolio deposit, but due to the influence of market policy, interest rate, liquidity, force majeure and other factors during the investment period, the relevant investment products may not achieve the expected income.
(II) risk control measures
1. The company has formulated relevant management systems in accordance with the Listing Rules of Shenzhen Stock Exchange and other relevant system requirements, and stipulated the staffing, account and fund management system, decision-making procedures, reporting system, internal control and risk monitoring management measures;
2. The financial department of the company shall strengthen the research and analysis of various cash management products, review the content and risk assessment of the products, and reasonably determine the cash management products purchased by the company; Timely analyze and track the investment direction of investment products, project progress, changes in net value of products, etc. if the assessment finds that there are risk factors that may affect the safety of the company’s funds, corresponding preservation measures will be taken in time to control investment risks.
3. The internal audit department of the company shall regularly inspect the use and storage of the raised funds and timely report the inspection results to the audit committee.
4. The independent directors of the company have the right to supervise and inspect the use and storage of the raised funds, and can hire an accounting firm to issue an assurance report when necessary.
5. The board of supervisors and the recommendation institution of the company shall supervise and inspect the use and storage of the raised funds. 6. The company will timely perform the obligation of information disclosure in accordance with the relevant provisions of Shenzhen Stock Exchange.
3、 Impact on the company
The company’s use of temporarily idle raised funds for cash management is implemented on the premise of ensuring the funds required for the company’s raised investment projects and ensuring the safety of the raised funds. There is no behavior of changing the purpose of the raised funds in a disguised manner and will not affect the normal progress of the company’s raised funds projects. Appropriate low-risk cash management can improve the use efficiency of idle raised funds and obtain certain investment income, which is in line with the interests of the company and all shareholders.
4、 The company’s use of idle raised funds for cash management in the first 12 months
As of the date of this announcement, except for the products disclosed in this announcement, the company did not use the raised funds for cash management in the first 12 months.
5、 Documents for future reference
1. Relevant agreements;
2. Other documents required by China Securities Regulatory Commission and Shenzhen Stock Exchange.
It is hereby announced
Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) board of directors
May 21, 2002
